Brain metastases in adenocarcinoma of the lung: frequency, risk groups, and prognosis.

http://jco.ascopubs.org/content/6/9/1474.short

Journal of Clinical Oncology

jco.ascopubs.org JCO September 1988 vol. 6 no. 9 1474-1480 1988 by American Society of Clinical Oncology

J B Srensen, H H Hansen, M Hansen and P Dombernowsky

+

Author Affiliations

Abstract
A consecutive group of 259 patients with inoperable adenocarcinoma of the lung (ACL) were observed to define risk groups for and frequency of brain metastases together with prognosis. All patients received chemotherapy in a three-armed randomized trial. Brain metastases were diagnosed in 25 patients before protocol entry and in 37 during treatment. Brain autopsy was performed in 87 patients and was positive in 38 (44%). Eleven of these (29%) were not diagnosed clinically. Patients younger than 60 years had a somewhat higher overall frequency of brain metastases than older patients. Patients with initial performance status above 60% and patients responding to chemotherapy had higher risk for developing brain metastasis during treatment than other patients, probably because of the increasing cumulated risk for this complication with prolonged survival. Median survival after onset of brain metastases was 73 days and survival was significantly shorter for these patients than for patients without this complication at days 0, 90, 180, and 365 after protocol entry. Thus, brain metastases is a frequent complication in ACL and the frequency increases with prolonged survival. Survival after development of brain metastases is short and it is questionable whether the inclusion of this subgroup of ACL patients into experimental cytostatic treatments is justified.

Articles citing this article

Brain metastases from lung cancer responding to erlotinib: the importance of EGFR mutation Eur Respir J Mar 1, 2011:624-631 [Abstract] [Full Text] [PDF]

EGFR mutation status and survival after diagnosis of brain metastasis in nonsmall cell lung cancer Neuro Oncol Nov 1, 2010:1193-1199 [Abstract] [Full Text] [PDF]

A randomized, phase III multicenter trial of gemcitabine in combination with carboplatin or paclitaxel versus paclitaxel plus

1 of 2

3/8/2012 9:17 PM

Brain metastases in adenocarcinoma of the lung: frequency, risk groups, and prognosis.

http://jco.ascopubs.org/content/6/9/1474.short

carboplatin in patients with advanced or metastatic non-small-cell lung cancer Ann Oncol Mar 1, 2010:540-547 [Abstract] [Full Text] [PDF]

Flt3L and TK gene therapy eradicate multifocal glioma in a syngeneic glioblastoma model Neuro Oncol Feb 1, 2008:19-31 [Abstract] [Full Text] [PDF]

Radiotherapy in Lung Adenocarcinoma with Brain Metastases: Effects of Activating Epidermal Growth Factor Receptor Mutations on Clinical Response Clin. Cancer Res. Jan 1, 2008:162-168 [Abstract] [Full Text] [PDF]

Use of Temozolomide with Other Cytotoxic Chemotherapy in the Treatment of Patients with Recurrent Brain Metastases from Lung Cancer The Oncologist Feb 1, 2003:69-75 [Abstract] [Full Text] [PDF]

2 of 2

3/8/2012 9:17 PM